A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

November 7, 2018

Study Completion Date

November 7, 2018

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

MPDL3280A

Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.

RADIATION

Hypofractionated Radiotherapy

Hypofractionated Image-Guided Radiotherapy (HIGRT)

Trial Locations (2)

48109

The University of Michigan Comprehensive Cancer Center, Ann Arbor

Unknown

University of Washington, Seattle, Seattle

All Listed Sponsors
collaborator

University of Washington

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER

NCT02463994 - A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | Biotech Hunter | Biotech Hunter